Bibf (Ofev (approved for pulmonary fibrosis), Vargatef (approved for lung cancer in some regions))
Kinase Inhibitor · Approved since 2014
Description
BIBF 1120 (nintedanib) is an oral multi-kinase inhibitor that targets angiogenic and fibrotic pathways in cancer treatment. In colorectal cancer, it has been evaluated as an anti-angiogenic agent, potentially serving as an alternative to bevacizumab in metastatic disease. The drug was tested in combination with standard chemotherapy regimens including mFOLFOX6 for patients with advanced, chemotherapy-refractory colorectal cancer.
Mechanism of Action
BIBF 1120 simultaneously inhibits multiple receptor tyrosine kinases including VEGFR (vascular endothelial growth factor receptor), PDGFR (platelet-derived growth factor receptor), and FGFR (fibroblast growth factor receptor). By blocking these angiogenic signaling pathways, the drug disrupts tumor blood vessel formation and maintenance, potentially limiting tumor growth and metastasis.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Ofev (approved for pulmonary fibrosis), Vargatef (approved for lung cancer in some regions) |
| Category | Kinase Inhibitor |
 Status | Off-label |
| Administration | Oral |
| Year Approved | 2014 |
| Clinical Trials | 3 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.